



AstraZeneca

in conjunction with



UNIVERSITY of MARYLAND
SCHOOL OF PHARMACY

Post-Doctoral Fellowship

Early Oncology Clinical Development

2027 - 2029



in conjunction with
The University of Maryland School of Pharmacy

Post-Doctoral Fellowship

Early Oncology Clinical Development
2027 - 2029


ABOUT ASTRAZENECA



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of life-changing medicines that contribute value to patients and society. AstraZeneca's innovative science and leadership are concentrated in three main therapy areas: oncology; respiratory; cardiovascular, renal, and metabolic disease (CVRM).

AstraZeneca North America research operations are headquartered in **Gaithersburg, Maryland** (25 miles from Washington, DC) one of AstraZeneca's Five global R&D centers, with additional sites in **Cambridge, MA; Cambridge, United Kingdom; Gothenburg, Sweden; Shanghai and Beijing, China**. With a drive to follow the science, AstraZeneca employs some of the best scientific minds in the industry who continually push the boundaries of science to deliver life-changing medicines.

AstraZeneca currently has 196 projects in development with 19 new molecular entities in late-stage trials, and 1 new molecular entities under review - one of the most robust pipelines in the industry. The Gaithersburg site includes ~5,000 employees in a state-of-the-art building that supports drug development from discovery to clinical development.



Gaithersburg, Maryland, USA



Cambridge, United Kingdom



Cambridge, Massachusetts, USA



Barcelona, Spain

OUR PURPOSE AND VALUES



We follow the science

Each of our individual perspectives gives meaning to our data and insights. We are encouraged to be curious about our ideas and those of the people around us and explore new innovations and technologies to help develop breakthrough solutions, which will have an impact on our patients lives.



We put patients first

We strive to understand patients' needs considering them in every decision we take.



We play to win

Our different backgrounds and perspectives compliment the work we do and help achieve not only AstraZeneca's goals but our own professional and personal ones too. We have created a safe place, encouraging our people to come together as a team to speak up in order to develop our ways of working and keep striving for continuous improvement and innovation.



We do the right thing

Doing the right thing is an essential part of who we are and is key to achieving our ethical business objectives. It is a behavior that also translates to our personal values. We have created an environment for open communication, enhancing collaboration and encouraging innovation, with team members who continuously strive for the best outcomes and behaviors.



We are entrepreneurial

We encourage our teams to work collaboratively and take ownership of their ways of working to drive continuous improvements that create change. We achieve this by taking smart risks to find effective solutions when bringing new ideas to life.



OVERVIEW and OBJECTIVES

The University of Maryland –AstraZeneca fellowship program provides intensive, specialized training to understand the drug development process and study management experience with emphasis on the development of the post-doctoral individual to succeed in the pharmaceutical industry. The intent is to prepare the fellow with an exceptional learning and mentorship experience as they enter their longer-term career in drug development.

The AstraZeneca-University of Maryland Clinical Development Fellowship is an exclusive 2-year program geared toward PharmD and PhD graduates with a passion for clinical research in the pharmaceutical and biotechnology industries. Established in 2009, the fellowship has paved the career path for numerous to enter clinical development.

The fellowship position will be recruited for in the 2027-2029 cycle located at the Gaithersburg, MD office

Fellows in the program will be involved in the early clinical development of oncology therapeutics. These pharmaceutical products may include biologics and small molecules, as well as exciting new modalities (including ADCs and Immunotherapies). The key learning objectives of the fellowship program are to understand:

- Scientific research process (including hypothesis generation and development)
- Clinical Development role and part of a Study Team
- Protocol development and study design
- Clinical development plans
- Understanding of oncology efficacy and safety assessments
- Data analysis, interpretation, and presentation
- Preparation and review of safety narratives
- Presentation to internal and external stakeholders
- Professional communication including verbal and written
- Preceptorship of 4th year PharmD students from University of Maryland

EARLY ONCOLOGY RESEARCH & DEVELOPMENT - EXECUTIVE LEADERSHIP



Pascal Soriot
Chief Executive Officer
AstraZeneca



Susan Galbraith
MB., BChir., PhD
Executive Vice President
Oncology R&D



Italia Grenga, MD
Vice President
Early Oncology Clinical Development
Early Oncology & Precision Medicine

FELLOWSHIP LEADERSHIP

Program Director



Oday Hamid
PharmD
Sr. Group Director
Early Oncology
Clinical Development
Scientist
Gaithersburg, MD

Program Co-Director



Natalia Ceacovscaia
PharmD
Senior Director
Early Oncology
Clinical Development
Scientist
Gaithersburg, MD

Program Co-Director



Alkis Papachristos
PhD, PharmD
Director
Early Oncology
Clinical Development
Scientist
Cambridge, MA

FELLOWSHIP SELECTION COMMITTEE



Simon Watkins, PhD
Executive Director (Interim)
Early Oncology Clinical Development
Early Oncology & Precision Medicine
Cambridge, UK



Oday Hamid
PharmD
Sr. Group Director
Early Oncology Clinical Development
Scientists
Gaithersburg, MD



Natalia Ceacovscaia
PharmD
Senior Director
Early Oncology Clinical Development
Scientists
Gaithersburg, MD



Sharad Verma PhD
Senior Director
Early Oncology Clinical
Development
Scientists
Gaithersburg, MD



Veronique Bragulat
PhD
Director
Early Oncology Clinical
Development
Scientists
Gaithersburg, MD



Alkis Papachristos
PhD, PharmD
Director
Early Oncology Clinical Development
Scientists
Cambridge, MA



Felopater Faheem
PharmD
2nd Year Fellow
Early Oncology Clinical Development
Scientists
Gaithersburg, MD

CURRENT FELLOWS

2nd Year



Felopater Faheem
PharmD

Early Oncology Clinical Development - Scientists
University of North Carolina
School of Pharmacy

1st Year



Sharvari Dharmaiah
PhD

Early Oncology Clinical Development - Scientists
UT MD Anderson Cancer Center UTHouston GSBS
Cancer Biology & Therapeutics and Pharmacology



Lilian Zhang
PharmD

Early Oncology Clinical Development- Scientists
University of Michigan College of Pharmacy

FELLOWSHIP PARTNERSHIP



Oday Hamid, PharmD

Fellowship Director

Senior Group Director

Early Oncology Clinical Development - Scientists

AstraZeneca



The University of Maryland –AstraZeneca fellowship program provides intensive, specialized training to understand the drug development process and study management experience with emphasis on the development of the post-doctoral individual to succeed in the pharmaceutical industry. The intent is to prepare the fellow with an exceptional learning and mentorship experience as they enter their longer-term career in drug development.



Audra Stinchcomb, RPh, PhD

Fellowship Program Director

Professor of Pharmaceutical Sciences

University of Maryland School of Pharmacy



UNIVERSITY of MARYLAND
SCHOOL OF PHARMACY

The University of Maryland School of Pharmacy's partnership with AstraZeneca makes available a unique clinical development fellowship to new graduates who are interested in pursuing careers in the pharmaceutical and biotechnology industries. This fellowship not only provides a wonderful training opportunity for outstanding graduates but also creates a pipeline for the development of highly qualified scientists who will be at the forefront of creating new medicines for the treatment of a variety of diseases. This innovative educational and research opportunity allows fellows to experience firsthand the work environment and challenges of the pharmaceutical industry. Furthermore, the fellowship allows students to leverage their PharmD education and apply it to real-world applications. As evidenced by the success of former fellows, AstraZeneca Clinical Development Fellows are uniquely positioned to compete in the highly competitive pharmaceutical and biotechnology industry. Thus, this opportunity provides an exciting springboard for a highly successful career at AstraZeneca and beyond.

STATEMENTS FROM FORMER FELLOWS

Alula Yohannes, PharmD, MS

Director, Early Oncology Clinical Development – Scientists, AstraZeneca *Completed 2022*



The fellowship afforded me the opportunity to learn about the drug development process and was structured to optimize my exposure to different stages of clinical development. I was constantly learning and applying new concepts and engaging in real time clinical study management while working with a team of experienced and dedicated clinical professionals who fostered an environment of collaboration and cooperation that accelerated my learning process and made AstraZeneca a great place to work. The program was challenging yet rewarding while preparing me for my professional career journey in oncology clinical development.

Stephanie Udoye, PharmD

Global Scientist Director, Late Oncology, AstraZeneca *Completed 2020*



This fellowship is a unique opportunity to immerse oneself in the dynamic role a clinical scientist plays in the drug development process. It arms fellows with the skills needed to act as contributing members to the clinical development team, working towards curating novel therapies and combination treatments for populations with high unmet needs. A spirit of innovation and collaboration thrives at AstraZeneca, fostering an open environment for ample learning and creativity. The fellowship opens the door to training opportunities that adequately prepare its fellows for a career in industry.

Benjamin Ridgway, PharmD, MS

Associate Director, Early Oncology Clinical Development –Scientists, AstraZeneca *Completed 2021*



The AstraZeneca-University of Maryland post-doctoral fellowship provides recent graduates with an avenue to learn the fundamentals of drug development, answering some of the most relevant and engaging clinical questions while working alongside experienced professionals who are invested in student success. This means the chance to join a team of industry veterans tackling the unique challenges that arise from running innovative trials of novel drugs, from monitoring for safety signals to establishing a dose to take to later stage trials, all with the aim of improving the lives of patients.

Elie Pommier, PharmD

Associate Director, Early Oncology Clinical Development –Scientists, AstraZeneca *Completed 2024*



Through the clinical drug development post-doctoral program at AstraZeneca, I was able to learn invaluable skills such as understanding clinical trial design, protocol development, the scientific research process, and much more. Through this opportunity, I was also able to apply the clinical science I had learned in school to help assess patient profiles for safety as well as the efficacy of the investigational drugs we work on here at AstraZeneca.

REQUIREMENTS - PharmD Background

1. Applicant is currently in 4th year of pharmacy school or has graduated from School of Pharmacy by spring 2027 (fellowship starts on the first week of July 2027). Applicants other than University of Maryland students may apply.
2. Applicants must be eligible to work in the USA and be willing to relocate/be on-site in Gaithersburg, MD office. No visa sponsorship is available.
3. Applicant has demonstrated strong interest in clinical research and has conducted research in relevant scientific fields such as oncology (preferred), biology/chemistry, toxicology, or pharmacokinetics/pharmacodynamics.
4. Applicant demonstrates leadership skills as well as sufficient communication (written and oral) skills as per prior curriculum requirements or presentation of prior research.

REQUIREMENTS - PhD Fellowship

1. Applicant will have completed their doctoral/post-doctoral training by spring 2027 in a scientific field (fellowship starts on the first week of July 2027). Applicants with post-doctoral experience are preferred. Applicants other than University of Maryland students may apply.
2. Applicants must be eligible to work in the USA and be willing to relocate/be on-site in the Gaithersburg, MD office. No visa sponsorship is available.
3. Applicant has demonstrated strong interest in clinical research and has conducted research in relevant scientific fields such as oncology (preferred), biology/chemistry, toxicology, or pharmacokinetics/pharmacodynamics.
4. Applicant demonstrates leadership skills as well as sufficient communication (written and oral) skills as per prior curriculum requirements or presentation of prior research.

APPLICATION PROCESS

Students will be evaluated by the Executive Committee at AstraZeneca and are required to submit the following documents:

1. The Fellowship Application Form including a one-page statement explaining career goals, research experiences, and interest in clinical research.
2. A curriculum vitae that highlights clinical, research, and work experience.
3. Submit two professional letters of recommendation addressed to Oday Hamid, PharmD (either prior employer and/or faculty; for PhD applicants – former PhD advisor/post-doctoral PI required) as instructed on the Fellowship Application Form.
4. A presentation is expected of candidates during the interview process.
5. Access website [here](#).



TIMELINES

Applicants will be interviewed on a rolling basis,
so early application is encouraged

Timeline	
APPLICATION PORTAL OPENS	September 14, 2026
SUBMISSION DEADLINE	October 31, 2026
LETTERS OF RECOMMENDATIONS DEADLINE	November 23, 2026
DECISION DATE	December 11, 2026

Address and email LORs to
Oday Hamid, PharmD (oday.hamid@astrazeneca.com)

For additional information on the program, please contact

- Audra Stinchcomb, PhD (astinchc@rx.umaryland.edu)
- Oday Hamid, PharmD (oday.hamid@astrazeneca.com)



in conjunction with





AstraZeneca 

in conjunction with



UNIVERSITY of MARYLAND
SCHOOL OF PHARMACY

Post-Doctoral Fellowship | Early Oncology Clinical Development